Monopar Therapeutics Inc. — Net Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6281e857-53a3-4337-a5f4-cf30bb153e71/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-13.7M | 2025-01-01 – 2025-12-31 | evidence 0001437749-26-014183 |
| FY 2024 | $-15.6M | 2024-01-01 – 2024-12-31 | evidence 0001437749-26-014183 |
| FY 2023 | $-8.4M | 2023-01-01 – 2023-12-31 | evidence 0001437749-26-014183 |
| FY 2022 | $-10.5M | 2022-01-01 – 2022-12-31 | evidence 0001654954-23-003384 |
| FY 2021 | $-9.1M | 2021-01-01 – 2021-12-31 | evidence 0001654954-22-003701 |
| FY 2020 | $-6.3M | 2020-01-01 – 2020-12-31 | evidence 0001654954-21-003243 |
| FY 2019 | $-4.2M | 2019-01-01 – 2019-12-31 | evidence 0001654954-20-003363 |
| FY 2018 | $-3.2M | 2018-01-01 – 2018-12-31 | evidence 0001654954-19-002003 |
| FY 2017 | $-16.6M | 2017-01-01 – 2017-12-31 | evidence 0001654954-18-003136 |
| FY 2016 | $-1.2M | 2016-01-01 – 2016-12-31 | evidence 0001654954-18-003136 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Monopar Therapeutics Inc. — all facts · Revenue · Operating Income